Difficulties accessing NHS stem cell transplants (also known as HSCT or AHSCT) for multiple sclerosis were highlighted in national newspapers this weekend. The articles reported how strict medical criteria often mean that people are not eligible for NHS treatment; some people who have been turned down have paid for private treatment at clinics in the UK and overseas. People in Scotland also struggle to get referrals despite the Scottish Health Technologies Group approving HSCT as an NHS treatment for highly active relapsing remitting MS.
One of the newspapers approached us for a comment but did not include our statement in their article – here’s our statement:
The MS Trust would like to see HSCT available at more specialist centres in the UK for people who have been shown to benefit the most. Several studies are being planned or are underway which will make the potential of HSCT clearer, helping us understand who is most likely to benefit from it and how it compares to other treatments, both in the short and in the long term.
We know that HSCT can be very effective for people with highly active multiple sclerosis, but it is an aggressive and demanding treatment which carries a degree of risk and involves a lengthy recovery period. This makes it unacceptable for some people, while others welcome the potential of HSCT to “hit their MS hard” with a single course of treatment.
We recently interviewed Prof Basil Sharrack, a consultant neurologist involved in HSCT research in Sheffield. He answers some of the most frequently asked questions and describes StarMS, a new clinical trial which will recruit nearly 200 participants at 19 research centres around the UK. The study will compare highly effective disease modifying drugs with HSCT over a 24 month period. Find out more on the study website.
More about autologous haematopoietic stem cell transplantation (HSCT)
Autologous haematopoietic stem cell transplantation (HSCT) uses high doses of chemotherapy drugs to wipe out harmful cells in your immune system. Your own stem cells are used to “regrow” your immune system so that it no longer attacks myelin or causes inflammation in the brain and spinal cord.
Read more about stem cell transplants for MS
Ponesimod (Ponvory) for relapsing remitting multiple sclerosis rejected by NICE
13 Oct 2021 - 00:00
The MS Trust is very disappointed that NICE does not recommend ponesimod (Ponvory) as an NHS treatment in England and Wales.
Multiple sclerosis and disease modifying drugs, what are my options?
28 Sep 2021 - 00:00
We interview Dr Sharmilee Gnanapavan, a Consultant Neurologist at Bart's Health to get some answers on what's new in the world of disease modifying drugs and multiple sclerosis.
New report highlights barriers to accessing Sativex across the UK
18 Aug 2021 - 00:00
Fewer than 13% of people in England eligible for Sativex can access it, according to a new report published today. People living in Wales, Scotland and Northern Ireland also face difficulties.
Move it for MS Nick's story
7 Oct 2021 - 00:00
Nick, was diagnosed with relapsing remitting multiple sclerosis at the start of the first lockdown. In this story we talk to him about how he coped with his diagnosis and how running helps him with his MS.
David's diary - Inclusion and diversity, where are we now?
6 Oct 2021 - 00:00
Just over a year ago we published a diary entry about Inclusivity and Diversity at the MS Trust. In this piece we take a look at what's changed since then and what we still need to do.
Flu season 2021
4 Oct 2021 - 00:00
This year is likely to involve a bigger flu vaccination programme in the UK, including for people with multiple sclerosis (MS), due to the circulation of Covid-19 at the same time. Here we discuss who's eligible for a flu jab on the NHS and how to get one.
Sign up for updates from us
Keep up-to-date with the latest MS news, explore new research, read the stories of people living with MS, find out practical tips from MS experts, and discover exciting fundraising opportunities.